 |
| Advisory Board |
 |
Daniel Cohen
Chairman of Scientific Advisory Board
daniel.cohen@moleac.net |
Professor Daniel Cohen, 53, is a leading expert and pioneer in the field of genetics. Daniel Cohen is known as the founder of modern genetics, and the "Henry Ford" of the genome, since he was the first to industrialise and upscale the discovery process.
Daniel Cohen is the co-founder of CEPH, Centre d'Etude du Polymorphisme Humain, a non for profit organization devoted to genetic diseases. In the early 1980's, he has been the first scientist to envision, launch and conduct large scale analysis of the human genome, producing the first physical maps of the genome. Joining Genset with all his team in 1995, Daniel Cohen has directed number of R&D partnerships with big pharmas, delivering new data, targets and potential therapeutics in various fields, ranging from cancer to psychiatric diseases.
Professor Daniel Cohen was the first to introduce and develop the concept of pharmacogenomics, which led to the first agreement of its kind in this field between Genset and Abbott Laboratories in 1997.
Professor Daniel Cohen serves or has served as a scientific advisor to several biotech companies. He is also a recipient of numerous awards, including the Daniel Bauperthuy Prize from the French Academy of Sciences, and the American Academy of Achievement's Golden Plate Award. He is also Honoured Doctor from the University of Xian and from the University of Shanghai.
Professor Cohen has authored more than 100 scientific publications, in leading scientific journals. He is chevalier of French Legion of Honor.
Daniel Cohen co-founded Moleac with David Picard, Marc Vasseur and Bounmy Rattanavan. Daniel contributes his considerable expertise in genetic research and drug discovery and development.
|
|
|
Georges Charpak
george.charpak@moleac.net
|
Georges Charpak has been awarded the Nobel Prize in Physics in 1992 for his invention and development of particle detectors, in particular the multiwire proportional chamber, a breakthrough in the technique for exploring the innermost parts of matter.
Professor Charpak received a PhD in 1955 from the College de France, Paris, where he worked in the laboratory of Fr¨¦d¨¦ric Joliot-Curie. In 1959 he joined the staff of European Laboratory for Particle Physics at CERN in Geneva and in 1984 became Joliot-Curie professor at the School of Advanced Studies in Physics and Chemistry, Paris. After working on spark chambers, which detect passing particles by emitting little bursts of current, in 1968 he invented the wire chamber. He was awarded the Physics Nobel Prize for 1992 for his significant contributions to the instrumentation used in experiments at high energy accelerators. Many new particles were discovered in the past few decades with detectors developed by Georges Charpak. By the 1990s, such detectors became indispensable to almost every experiment in particle physics.
Prrofessor Charpak's detectors have also applications for biological research and could replace photographic recording in applied radiobiology. For this purpose, Professor Charpak founded Biospace, an instrumentation company which develops and sells instruments for medical practice and biological research.
Professor Charpak is also non-executive Director of the investment fund Fimalac. During the past few years, he has concentrated his activities in developing tools for scientific training and is highly interested in new biological research such as the frontier R&D being conducted at Moleac.
Professor Charpak is advising Moleac on the key scientific opportunities and facilitates the access to the teaching experts for each opportunity. |
|
|
Etienne-Emile Beaulieu
etienne.baulieu@moleac.net
|
Etienne-Emile Beaulieu's research is dedicated to the metabolism of steroid hormones. He has mainly worked on hormone-dependent cancers and on hormone signals. Scientist, physician and medical researcher, he has made significant contributions to medical science including the development of abortion pill RU486, in addition to an anti-aging pill from a human hormone, DeHydroEpiAndrosterone, more commonly known as DHEA.
As medical scientist at French pharmaceutical company Roussel-Uclaf, Professor Beaulieu conducted the first clinical test of RU-486 and discovered that the compound was 80% effective in ending early pregnancies. In the 1970s, he discovered the progesterone receptor. He also documented, in 1982, the activity of RU-486, an antiprogesterone compound now marketed as an abortion pill. He was a Professor at the Faculty of Medicine in Paris. In the mid-1960s, Professor Beaulieu became a member of the World Health Organization.
His honorary distinctions include Professor at the Coll¨¨ge de France, former Director of the Hormone and Genetics laboratory of Institut National de la Sant¨¦ et de la Recherche M¨¦dicale (INSERM), and honorary member of the American Physiological Society.
Professor Beaulieu was conferred honorary degrees from several prestigious institutions including Tufts University, the Karolinska Institute, the University of Gand and the Worcester Foundation. He is Member of the US National Academy of Sciences and of the Royal Society of Medicine, London.
Professor Beaulieu is recipient of numerous awards including the Grand Prix Scientifique de la Fondation pour la Recherche M¨¦dicale and the National Award of the American Association for Clinical Chemistry. He is Commander of the French Legion of Honor and a Chevalier of the French National Order of Merit. He was recently elected to the Presidency of the French Academie des Sciences.
Professor Beaulieu is advising Moleac on the key scientific opportunities and facilitates the access to the teaching experts for each opportunity. |
|
|
Shi Xue Min
xuemin.shi@moleac.net
|
Shi Xuemin is a highly respected Acupuncture expert and a Traditional Chinese Medicine clinician worldwide. In 1999 he was elected Academician at the Chinese Academy of Engineering.
Professor Shi is the inventor of several drugs including the drug he developed successfully in China to improve the recovery after cerebral infarct. This drug together with several others is now being taking into mainstream western medicine by Moleac. He cofounded Shitian Pharmaceuticals in Tianjin.
Professor Shi has been working on the clinical research of Acupuncture for more than 40 years. Among his numerous medical contributions, he first raised the theory of "quantity of Acupuncture manipulation'' thus enabling Acupuncture therapy to evolve towards standardized approaches. He also pioneered the combined analysis of symptoms and signs of Traditional Chinese Medicine with the diagnosis of Western medicine. Professor Shi is well known for having established the Acupuncture therapy of Xing Nao Kai Qiao.
Professor Shi was appointed president of the First Teaching Hospital of Tianjin University of Traditional Chinese Medicine in 1983, and moved to an Honorary President position in 2003. The First Teaching Hospital is the largest hospital for Traditional Chinese medicine in China, with about 600 beds dedicated to Acupuncture (out of a total of 2000) and about 800 daily out-patients in the acupuncture department. The acupuncture department has about 160 doctors, including 16 MDs and phDs.
Professor Shi is the Associate Director of the Society of State Acupuncture and Moxibustion, Director of Tianjin Society of Acupuncture and Moxibustion, Deputy Chairman of China Clinical Research Institute, First Vice President of Traditional Chinese Medical College of Bayer (Germany), consultant of American Oriental Medical Foundation, Honorary President of American College of Traditional Chinese Medicine, President of Hong Kong Hospital of Traditional Chinese Medicine.
In addition to his participation in the Scientific Advisory Board, Shi Xuemin is implementing with his team several scientific collaborations for the identification and development of new drugs. |
|
|
Han Ji Sheng
jisheng.han@moleac.net
|
Professor Han Ji-Sheng brings with him over 30 years experience in physiology and neurobiology. One of his main areas of research is the study of molecular events triggered by acupuncture treatment, particularly for pain relief. Professor Han has published over 400 articles and authored seven books on the study of neurochemical basis of acupuncture-induced analgesia; and molecular biology of neurotransmitters and neuropeptides in CNS.
Professor Han is the Director for the Department of Neurobiology, Peking University; Director for Key Laboratory of Neurosciences Research, Ministry of Education, China; Director for Neuroscience Research Institute, Peking University; Director for Key Laboratory of Neuroscience Research, Ministry of Public Health, China; President for Chinese Association for the Study of Pain; and Chairman of the Board of Medical Sciences, Foundation of Post-Doctoral Fellowship. Professor Han is also a Scientific Advisor to the World Health Organisation; Consultant to the Scientific Review Committee of NIH, and ADAMHA and a Member of the Executive Committee of the International Narcotic Research Conference.
In addition, he is also editor for several leading scientific journals in China.
His research in molecular acupuncture has attracted keen interest from the international scientific community. Professor Han has lectured at more than 100 universities worldwide, including the world renowned Duke, Stanford and Harvard universities in the US, and the University of London. He was also speaker at several international scientific conferences including the 12th International Congress of Pharmacology and the Founder's lecture of the International Narcotic Research Conference.
In addition to his participation in the Scientific Advisory Board, Professor Han has entered an exclusive collaboration with Moleac for the development of smoking cessation therapies.
|
|
|
Michel Maurice Lazdunski
michel.lazdunski@moleac.net
|
World-renowned scientist, Michel Lazdunski has made internationally recognized contributions to research in pharmacology and pathology, ranging from understanding the mechanisms underlying antihypertensives, antidiabetics, and anesthetics, to the mechanisms of pain, cardiac arrhythmia, convulsions, and cerebral ischemia.
Professor Lazdunski is the international specialist of ion channels and their pharmacology and over the last 25 years, he and his team have elucidated the molecular properties of the structure and functioning of ion channels.
Professor Lazdunski is a professor of pharmacology at the University of Nice and the Institut Universitaire de France; he is the founder and Director of the CNRS Institute of Molecular and Cell Pharmacology in Sophia Antipolis.
Professor Lazdunski has received several prestigious awards, such as the Grand Prix of the French Academy of Sciences for biological research (Charles L¨¦opold Mayer Prize) in 1983, the International Society for Cardiac Research Prize in 1984, the Ath¨¦na Foundation - Institut de France Prize in 1991, and the Grand Prix of the French Academy of Sciences for research of importance to the medical field. In 1991, he received the Bristol-Myers Foundation Neuroscience Award. He won the CNRS Gold Medal in 2000.
Professor Lazdunski is a member of several academies, including the French Academy of Sciences. He serves on a number of scientific and administration boards. He is also an officer of the Legion of Honor and of the National Order of Merit.
Professor Lazdunski will play a key role in guiding the Moleac team in the stroke and migraine therapeutic areas of research. |
|
|
Zhao Guo Ping
guoping.zhao@moleac.net
|
Professor Zhao Guo Ping joined Moleac as member of its Scientific Advisory board in late 2003.
Professor Zhao is one of China's leading experts in molecular biology and genetics. He is Professor and Executive Director of the Chinese National Human Genome Centre and Director and Vice President of the Chinese National Research Centre for Biochip Engineering. As one of the three Principal Scientists, Professor Zhao was responsible for the Human Genome Project of the Chinese Academy of Sciences (CAS) from 1998 to 2001. In addition, he has coordinated several bacterial genomics projects in China, including an ongoing Chinese Single Nucleotid Polymorphisms (SNP) project sponsored by the National High Technology Research and Development Programme.
Professor Zhao also spearheads several prominent scientific research bodies. He is Chairman of the Academic Committee, Institutes of Plant Physiology and Ecology, Shanghai Institute of Biological Science (SIBS), CAS; Chairman of Academic Committee, Shanghai Information Centre for Life Sciences, SIBS, CAS; and Chairman of Biotechnology Committee, Bureau of Life Sciences and Biotechnology, CAS.
Since the early nineties, Professor Zhao has focused on research in genomics, protein structure function relationship, metabolic regulation in microorganisms, and applied microbiology and biotechnology. Professor Zhao has written almost sixty research papers and abstracts for leading academic journals and scientific symposiums. He currently holds more than ten scientific patents.
Professor Zhao is playing a key role in facilitating the implementation of academic collaborations between Moleac and its numerous high profile institutions in Shanghai.
|
| |
|
|
 |
